乙酰丙酮酸乙酯 | 615-79-2

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 中文名称: 乙酰丙酮酸乙酯
• 中文别名: 2,4-二酮戊酸乙酯；丙酮草酸乙酯；2,4-二氧戊酸乙酯
• 英文名称: Ethyl 2,4-dioxopentanoate
• 英文别名: ethyl 2,4-diketopentanoate；ethyl 2,4-dioxovalerate
• CAS: 615-79-2
• 化学式: C₇H₁₀O₄
• mdl: MFCD00009124
• 分子量: 158.154
• InChiKey: OYQVQWIASIXXRT-UHFFFAOYSA-N

物化性质

• 熔点：
  16-18 °C (lit.)
• 沸点：
  101-103 °C/12 mmHg (lit.)
• 密度：
  1.126 g/mL at 25 °C (lit.)
• 闪点：
  >230 °F
• 溶解度：
  可溶于氯仿、甲醇
• 介电常数：
  16.1（19℃）
• 稳定性/保质期：
  性质与稳定性：在常温常压下，不会发生分解反应。

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  60.4
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 安全说明：
  S23,S24/25
• 危险类别码：
  R22
• WGK Germany：
  3
• 海关编码：
  29183000
• 危险品运输编号：
  NONH for all modes of transport
• 储存条件：
  贮存： 将密器密封，储存在密封的主容器中，并放置于阴凉、干燥处。

SDS

Name:	Ethyl 2 4-dioxovalerate 98% Material Safety Data Sheet
Synonym:	None
CAS:	615-79-2

Section 1 - Chemical Product MSDS Name:Ethyl 2 4-dioxovalerate 98% Material Safety Data Sheet
Synonym:None

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
615-79-2	Ethyl 2,4-dioxovalerate	98	210-447-5

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 615-79-2: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: clear very slight yellow
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 101 - 103 deg C @ 12.00mmHg
Freezing/Melting Point: 16.00 - 18.00 deg C
Autoignition Temperature: Not applicable.
Flash Point: > 112 deg C (> 233.60 deg F)
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water: Not available.
Specific Gravity/Density: 1.1260g/cm3
Molecular Formula: C7H10O4
Molecular Weight: 158.15

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, strong oxidants.
Incompatibilities with Other Materials:
Acids, bases, oxidizing agents, reducing agents.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 615-79-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Ethyl 2,4-dioxovalerate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 615-79-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 615-79-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 615-79-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

化学性质： 这是一种无色液体。其熔点为16至18℃，沸点在101至103℃（1.6 kPa），相对密度为1.126，折光率为1.4730（20℃）。该物质能溶于醇和醚，但不溶于水。

用途： 乙酰丙酮酸乙酯是医药磺安甲基异噁唑的中间体。

生产方法： 通过草酸二酯与丙酮缩合（克氏反应）制备。具体步骤为：将甲醇钠在40至45℃下滴入草酸二乙酯及丙酮中，保温1小时后冷却，再逐滴滴加浓硫酸至pH值降至3.5。接着用苯进行萃取，并蒸除苯。最后，在减压条件下蒸馏得到的产物，收集温度为130至132℃（4.93 kPa）的馏分即为所需的乙酰丙酮酸乙酯。

反应信息

• 作为反应物：
  描述：

  乙酰丙酮酸乙酯 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 生成 乙酰丙酮酸
  参考文献：
  名称：

  Discovery of α,γ-Diketo Acids as Potent Selective and Reversible Inhibitors of Hepatitis C Virus NS5b RNA-Dependent RNA Polymerase

  摘要：

  alpha,gamma-Diketo acids (DKA) were discovered from screening as selective and reversible inhibitors of hepatitis C virus NS5b RNA-dependent RNA polymerase. The diketo acid moiety proved essential for activity, while substitution on the gamma position was necessary for selectivity and potency. Optimization led to the identification of a DKA inhibitor of NS5b polymerase with IC50 = 45 nM, one of the most potent HCV NS5b polymerase inhibitors reported.

  DOI：

  10.1021/jm0342109
• 作为产物：
  描述：

  草酸二乙酯 在 ammonium chloride 作用下， 以 乙醇 、 丙酮 为溶剂， 生成 乙酰丙酮酸乙酯
  参考文献：
  名称：

  Synthesis of camptothecin and analogs thereof

  摘要：

  使用一种新型含羟基的三环中间体合成紫杉醇和紫杉醇类似物的方法，以及由该过程产生的紫杉醇类似物。这些紫杉醇类似物是有效的拓扑异构酶I抑制剂，并显示出抗白血病和抗肿瘤活性。

  公开号：

  US04981968A1
• 作为试剂：
  描述：

  3-methyl-2-methylthiobenzothiazolium methylsulfate 在 乙醇 、 三乙胺 、 乙酰丙酮酸乙酯 作用下， 生成 benzothiazol-2-ylacetone N-methyl enaminone
  参考文献：
  名称：

  Van Dormael; Ghys, Bulletin des Societes Chimiques Belges, 1948, vol. 57, p. 24,29

  摘要：

  DOI：

文献信息

• [EN] CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF<br/>[FR] MODULATEURS DE CALPAÏNE ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：BLADE THERAPEUTICS INC

  公开号：WO2019190885A1

  公开（公告）日：2019-10-03

  Small molecule calpain modulator compounds, including their pharmaceutically acceptable salts, can be included in pharmaceutical compositions. The compounds can be useful in inhibiting calpain, or competitive binding with calpastatin, by contacting them with CAPN1, CAPN2, and/or CAPN9 enzymes residing inside a subject. The compounds and composition can also be administered to a subject in order to treat a fibrotic disease or a secondary disease state or condition of a fibrotic disease.

  小分子钙蛋白酶调节剂化合物，包括其药用可接受的盐，可以包含在药物组合物中。这些化合物可以通过与主体内的CAPN1、CAPN2和/或CAPN9酶接触来抑制钙蛋白酶，或与钙蛋白酶抑制剂竞争性结合。这些化合物和组合物也可以被用于治疗纤维化疾病或纤维化疾病的继发疾病状态或病情。
• [EN] NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS 6-AMINO-QUINOLINONE ET DÉRIVÉS EN TANT QU'INHIBITEURS DE BCL6
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2018108704A1

  公开（公告）日：2018-06-21

  The present invention encompasses compounds of formula (I), wherein the groups R1 to R5, X, Y and W have the meanings given in the claims and specification, their use as inhibitors of BCL6, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.

  本发明涵盖了式(I)的化合物，其中基团R1至R5、X、Y和W具有权利要求和说明中给定的含义，它们作为BCL6的抑制剂的用途，含有这种化合物的药物组合物以及它们作为药物的用途，特别是作为治疗和/或预防肿瘤疾病的药剂。
• Design, synthesis, antifungal activity and 3D-QSAR study of novel pyrazole carboxamide and niacinamide derivatives containing benzimidazole moiety
  作者：Wei-Jie Si、Xiao-Bin Wang、Min Chen、Meng-Qi Wang、Ai-Min Lu、Chun-Long Yang

  DOI：10.1039/c8nj05150j

  日期：——

  series of novel pyrazole carboxamide and niacinamide derivatives containing a benzimidazole moiety were designed and synthesized as antifungal candidate agents. All target compounds were characterized by FTIR, 1H NMR, 13C NMR, HRMS and elemental analysis techniques. The structure of compound T1 was further confirmed by single crystal X-ray diffraction analysis. The antifungal activities of the target

  设计并合成了一系列含有苯并咪唑部分的新型吡唑羧酰胺和烟酰胺衍生物，作为抗真菌候选药物。所有目标化合物均通过FTIR，1 H NMR，13 C NMR，HRMS和元素分析技术进行了表征。化合物T1的结构通过单晶X射线衍射分析进一步确认。在体外评估了目标化合物对四种植物病原真菌（灰葡萄孢，立枯根瘤菌，禾谷镰刀菌和黑斑病菌）的抗真菌活性。）通过菌丝体生长抑制方法。生物测定结果表明，一些化合物对显示出良好的抗真菌活性灰霉病以100μgML -1相比其他三个真菌。为了更好地探索结构-活性关系（SAR），测定并评估了目标化合物对灰葡萄孢的EC 50值。随后，基于被测化合物对灰葡萄孢的抑制活性，使用比较分子场分析（CoMFA）技术进行了3D定量结构-活性关系（3D-QSAR）研究。分子建模结果显示具有交叉验证的q 2的良好预测能力和非交叉验证的r 2值分别为0.578和0.850。
• [EN] 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS<br/>[FR] 1H-PYRAZOLO [4,3-B] PYRIDINES EN TANT QU'INHIBITEURS DE PDE1
  申请人：H LUNDBECK AS

  公开号：WO2018007249A1

  公开（公告）日：2018-01-11

  The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

  本发明提供了式(I)的1H-吡唑并[4,3-b]吡啶-7-胺作为PDE1抑制剂，并将其用作药物，特别用于治疗神经退行性疾病和精神疾病。
• MACROCYCLES AS PDE1 INHIBITORS
  申请人：H. Lundbeck A/S

  公开号：US20190185489A1

  公开（公告）日：2019-06-20

  The present invention provides macrocycles of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

  本发明提供了式(I)的大环化合物作为PDE1抑制剂，并将其用作药物，特别用于治疗神经退行性疾病和精神疾病。

表征谱图